Daily MedNews
Printable Version   Email to a friend

Low Levels of Brain Chemical May Control Appetite

WEDNESDAY, Aug. 27 -- A chemical produced in the brain may play a role in regulating appetite and the likelihood of becoming obese, according to a new study.

For the study, researchers looked at a group of 33 people who had WAGR syndrome, a genetic condition that occurs in one in 500,000 to a million people. WAGR is an acronym for the symptoms that accompany the condition: Wilms' tumor (tumor of the kidneys), aniridia (absence of the iris), genital and urinary tract abnormalties, and mental retardation.

Some people with WAGR syndrome lack a gene for the brain chemical, brain-derived neurotrophic factor (BDNF). Animal studies have suggested that BDNF may help control appetite and weight.

The researchers found that 19 (58 percent) of the 33 study participants had deletions of all or a major proportion of one copy of the gene for BDNF and had correspondingly low blood levels of BDNF.

These 19 participants were all obese by age 10 and had a strong tendency to overeat. The participants who had two working copies of the BDNF gene, on the other hand, were no more likely to develop obesity in childhood than the general population and did not report unusually high levels of overeating.

"This is a promising new lead in the search for biological pathways that contribute to obesity," Dr. Duane Alexander, director of the U.S. National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), said in an institute press release. "This finding may eventually lead to the development of new drugs to regulate appetite in people who have not had success with other treatments."

The findings are published in the Aug. 28 issue of the New England Journal of Medicine.

According to senior study author Dr. Jack A. Yanovski, of the NICHD's Unit on Growth and Obesity, BDNF is thought to work in combination with a variety of other substances that regulate appetite and body weight, including the appetite-signaling hormone leptin.

Future research looking into the relationship between BDNF and leptin may lead to the development of new therapies for obesity.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about obesity.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 20, 2008
Audience: Consumers, endocrinological healthcare professionals [Posted 11/20/2008] Animas Corporation and FDA informed consumers...
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...